Pulmonary Arterial Hypertension (PAH) is a heterogeneous group of diseases with high mortality, difficult diagnosis, limited available treatment, and no cure. The Pulmonary Hypertension Breakthrough Initiative (PHBI) is dedicated to comprehensive biobanking of human lungs with PAH and controls, supported by a detailed clinical annotation of the accrued specimens. Having started in 2006, the PHBI successfully developed a novel and unique infrastructure, whose success relied on the active participation of a highly integrated network of university-based sites with extensive expertise in each of the spheres of competency: excellence in clinical care of PAH (including patient accruals), lung transplantation, pathology, genetics, genomics, and cell isolation. The goal of this application is to leverage these unparalled resources and unique expertise into an R24-supported initiative to direct the bank to accrue specimens of disease-specific groups, which will be highly integrated with pathologic, genetic, and genomic subphenotypes pertaining to not only lung and blood specimens, but now expanding to the failing PAH heart. This proposal will be highly synergistic with the presently supported initiatives by the NHLBI in the field. The flexibilty of our infrastructure and governance will allow us to be decidedly responsive and integrated with any future NHLBI initiatives. We propose that this unique infrastructure will serve the pressing roles of advancing the translation of key discoveries to the patients with PAH and to aid in new discoveries that will have a long lasting impact in the field. The following specific aims will be pursued:
Specific Aims of the Proposal 1) To establish a comprehensive biorepository of the specimens from subjects with pulmonary arterial hypertension and failed donor controls. 2) To provide the infrastructure to support human tissue based research in PAH via integrated cores devoted to Administration, Tissue Handling and Pathology, Cell Line Development, and Genomic Characterization and Cataloging. 3) To develop and implement an interface for consultation of research design and analysis to enhance broader scientific investigation.
Pulmonary Arterial Hypertension (PAH) is a very serious lung disease in which blood pressure in the lung's pulmonary artery increases making the heart work harder to pump blood into the lung. PAH is very rare with an annual incidence of 1 to 2 per million and occurs more often in women. While a certain fraction of patients have been found to have a hereditary predisposition to the disease, the cause remains unknown. Recent treatment advances have shown some benefit, but the disease has no cure. This project will provide a network of investigators to enroll patients who, at the time of lung transplantation, will donate their tissue and cells for future research. Completion of this work should aid in the development of newer diagnostic tests and more effective treatments.
|Dai, Zhiyu; Zhu, Maggie M; Peng, Yi et al. (2018) Endothelial and Smooth Muscle Cell Interaction via FoxM1 Signaling Mediates Vascular Remodeling and Pulmonary Hypertension. Am J Respir Crit Care Med 198:788-802|
|Rashid, Jahidur; Alobaida, Ahmad; Al-Hilal, Taslim A et al. (2018) Repurposing rosiglitazone, a PPAR-? agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH. J Control Release 280:113-123|
|Tang, Haiyang; Babicheva, Aleksandra; McDermott, Kimberly M et al. (2018) Endothelial HIF-2? contributes to severe pulmonary hypertension due to endothelial-to-mesenchymal transition. Am J Physiol Lung Cell Mol Physiol 314:L256-L275|
|Bohnen, Michael S; Ma, Lijiang; Zhu, Na et al. (2018) Loss-of-Function ABCC8 Mutations in Pulmonary Arterial Hypertension. Circ Genom Precis Med 11:e002087|
|Farkas, Daniela; Thompson, A A Roger; Bhagwani, Aneel R et al. (2018) Toll-like Receptor 3 is a Therapeutic Target for Pulmonary Hypertension. Am J Respir Crit Care Med :|
|Samokhin, Andriy O; Stephens, Thomas; Wertheim, Bradley M et al. (2018) NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension. Sci Transl Med 10:|
|Zhu, Na; Welch, Carrie L; Wang, Jiayao et al. (2018) Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease. Genome Med 10:56|
|Rashid, Jahidur; Nahar, Kamrun; Raut, Snehal et al. (2018) Fasudil and DETA NONOate, Loaded in a Peptide-Modified Liposomal Carrier, Slow PAH Progression upon Pulmonary Delivery. Mol Pharm 15:1755-1765|
|Sa, Silin; Gu, Mingxia; Chappell, James et al. (2017) Induced Pluripotent Stem Cell Model of Pulmonary Arterial Hypertension Reveals Novel Gene Expression and Patient Specificity. Am J Respir Crit Care Med 195:930-941|
|Tojais, Nancy F; Cao, Aiqin; Lai, Ying-Ju et al. (2017) Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-? in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension. Arterioscler Thromb Vasc Biol 37:1559-1569|
Showing the most recent 10 out of 68 publications